← Back to Search

Corticosteroid

Elotuzumab + Pomalidamide + Low Dose Dexamethasone (EPd) for Multiple Myeloma

Phase 2

Waitlist Available

Research Sponsored by Bristol-Myers Squibb

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from first dose to study completion date (up to approximately 50 months)

Awards & highlights

All Individual Drugs Already Approved

Approved for 60 Other Conditions

No Placebo-Only Group

Summary

Study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd Cohort) and elotuzumab in combination with nivolumab (EN Cohort) to assess the safety and efficacy of these combination therapies for treatment of relapsed or refractory MM patients.

Eligible Conditions

Multiple Myeloma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from first dose to study completion date (up to approximately 50 months)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from first dose to study completion date (up to approximately 50 months)

This trial's timeline: 3 weeks for screening, Varies for treatment, and from first dose to study completion date (up to approximately 50 months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Secondary study objectives

Objective Response Rate (ORR)

Overall Survival (OS)

Progression Free Survival (PFS)

Awards & Highlights

All Individual Drugs Already Approved

Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Approved for 60 Other Conditions

This treatment demonstrated efficacy for 60 other conditions.

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Elotuzumab + Pomalidamide + Low Dose Dexamethasone (EPd)Experimental Treatment4 Interventions

patients will receive treatment with elotuzumab in combination with pomalidomide and low-dose dexamethasone. Patients are eligible to receive Nivolumab at progression.

Group II: Elotuzumab + Nivolumab (EN)Experimental Treatment2 Interventions

Patients will receive treatment with a combination of elotuzumab and nivolumab

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Elotuzumab

FDA approved

Pomalidomide

FDA approved

Dexamethasone

FDA approved